| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Research
1 company
Jeff Fairman last filed a Form 4 in December 2022, as VP, Research at PCVX. From December 2020 to October 2022, the filings on record show 0 open-market purchases and 20 sales. Jeff Fairman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Jeff Fairman a below-average insider score of 44/100, based on 19 past trades. Over a 12-month horizon, 15.8% of those trades were profitable, with an average 12-month return of -54.6%.
At the last filing, the largest reported position was 286,227 shares of PCVX. The PCVX filings lean toward selling, a net 112,000 shares.
Shares as reported in the last Form 4 for each company; the most recent is from December 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 9, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 131 | $22.50 | $2,947.50 | -2.1% | +14.7% | +98.2% | |
| Oct 26, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $22.69 | $107,777.50 | -48.0% | -19.7% | +80.1% | |
| Sep 27, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $26.17 | $124,303.09 | -48.0% | -11.8% | -6.7% | |
| Aug 26, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $25.38 | $120,543.00 | -48.0% | -15.4% | +11.2% | |
| Jul 26, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $22.70 | $107,825.00 | -48.0% | +0.2% | +5.0% | |
| Jun 28, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $24.37 | $115,769.84 | -48.0% | +9.1% | -13.2% | |
| Jun 7, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 9,500 | $22.50 | $213,750.00 | -64.9% | +12.7% | -13.9% | |
| Mar 26, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $23.88 | $113,433.24 | -77.1% | -1.5% | +0.8% | |
| Feb 26, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $23.93 | $113,663.22 | -77.1% | - | - | |
| Jan 26, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $25.27 | $120,014.50 | -77.1% | - | - |